Loading company…
Shoreline Biosciences develops cell therapies based on induced pluripotent stem cells.
Founded in 2020 and based in San Diego, Shoreline Biosciences develops cell therapies using induced pluripotent stem cells, with a focus on natural killer cells and macrophages. Its platform is intended to produce scalable cell products for conditions including cancer. Kleanthis Xanthopoulos is CEO. In October 2021, Ally Bridge Group led a USD 140 million Series B round to advance the platform.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in